Thermo Fisher Scientific Inc. reported its financial results for the first quarter ended March 29, 2025, with revenue of $10.36 billion, which was flat compared to $10.34 billion in the same quarter of 2024, but exceeded analyst estimates of $10.23 billion. The company's adjusted diluted EPS for Q1 2025 was $5.15, beating estimates of $5.10, and an increase from $5.11 in the prior year.
Despite the Q1 beat, Thermo Fisher cut its annual profit forecast for 2025, now expecting adjusted profit in the range of $21.76 to $22.84 per share, down from its previous forecast of $23.10 to $23.50. This revision is attributed to an anticipated $400 million hit to its sales in China due to the U.S.-China tariff war and potential cuts to academic research funding by the Trump administration.
The company plans to mitigate these impacts through strategic actions, including an increase of approximately $2 billion in U.S. manufacturing investments, supply chain changes, and pricing adjustments. Marc N. Casper, chairman, president, and chief executive officer, expressed confidence in the company's ability to manage the current macroeconomic environment and continue enabling customer success.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.